

بسم الله الرهكن الرجيم

$\infty \infty \infty$

تم رفع هذه الرسالة بواسطة /صفاء محمود عبد الشافي

بقسم التوثيق الإلكتروني بمركز الشبكات وتكنولوجيا المعلومات دون

AIN SHAMS UNIVERSITY

Since 1992

Propries 1992

أدنى مسئولية عن محتوى هذه الرسالة.

ملاحظات: لايوجد



Fibroblast Gross Factor-23 and Carotid Artery Stiffness in Hemodialysis Patient

Thesis

Submitted for partial fulfillment for Master Degree in **Internal Medicine**

By

Salwa Yasser MohamMed Ali

(M.B.B.C.h.,)

Under Supervision Of

Prof. Dr. Hisham Mohamed Atef Abu Al-Layl

Professor of Internal Medicine and Nephrology Faculty of Medicine- Ain Shams University

Dr. Khaled Gouda Abdel Wahab

Lecturer of Internal Medicine and Nephrology Ain Shams University- Faculty of Medicine

Faculty of Medicine
Ain Shams University
2021



سورة البقرة الآية: ٣٢

Acknowledgment

- First, thanks are all due to **Allah** for Blessing this work until it has reached its end, as apart of his generous help throughout our life.
- It was an honor to work under the supervision of eminent professors, who lent me their whole hearted support and immense facilities as is their usual with their juniors. To them, I owe more than I can record. I would like to express my deepest gratitude and highest appreciation to professor Dr. Hesham Atif Abouelliel Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, for his continuous encouragement and generous support, no word can express my gratitude.
- Hussien Sayed Hussien, Lecturer of Internal Medicine and Nephrology, Faculty of Medicine, Ain shams University, who supervised this work with great interest and who gave me unlimited support throughout the work.
- I would like to express my scincere gratitude to **Dr. Nadia**Mottassem Elbarghouty, Consultant of Radiodiagnosis,
 Faculty of Medicine, Ain shams University, for supervising this work with great interest and gaving me unlimited support throughout the work.
- Finally, no words can express my deep appreciation and gratitude to my family for their never ending support and care.

Salwa Yasser Mohammed Ali

List of Contents

| Title | Page No. |
|------------------------------|----------|
| | |
| List of Tables | i |
| List of Figures | ii |
| List of Abbreviations | v |
| Introduction | 1 |
| Aim of the Work | 3 |
| Review of Literature | |
| Pathophysiology of FGF23 | 4 |
| Chronic Kidney Disease (CKD) | 16 |
| Arterial Stiffness | 31 |
| Patients and Methods | 44 |
| Results | 57 |
| Discussion | 73 |
| Summary | 82 |
| Conclusion | 86 |
| Recommendations | 87 |
| References | 88 |
| Arabic Sumamry | |

List of Tables

| Table No | o. Title Pa | ge No. |
|--------------------|--|--------|
| Table (1): | Stages of CKD by GFR and albuminuriacategor | ry 17 |
| Table (2): | Demographic data | 57 |
| Table (3): | Etiology of chronic kidney disease (CKD) | 58 |
| Table (4): | Demographic data | 59 |
| Table (5): | Renal function and hemoglobin level and other investigations results. | |
| Table (6): | Serum levels of Fibroblast Growth Factor (FGF-23) (Pg/dl) | |
| Table (7): | Showing the percentage of present to absplaques in Common Carotid artery. | |
| Table (8): | Showing the relation between Fibroblast Gro Factor-23 (FGF-23) and absent or present Plaque the common carotid artery. | s in |
| Table (9): | Showing the range and mean together with stand deviation of FGF23, pulse pressure and common carotid artery intima media thickness | non |
| Table (10): | The relation between Fibroblast Growth Factor (FGF -23) and parameters of arterial stiffness | |
| Table (11): | Demographic data and comorbidities | 66 |
| Table (12): | The relation between Fibroblast Growth Factor (FGF -23) and dialysis parameters | |

List of Figures

| Fig. No. | Title | Page No. |
|---------------------|--|---------------------|
| | | |
| Figure (1): | The FGF-23 bone–kidney axis | 6 |
| Figure (2): | Spectrum of FGF23 level in CKD | 11 |
| Figure (3): | The causes and consequences of arterial st | iffness33 |
| Figure (4): | Logiq 7 ultrasound | 52 |
| Figure (5): | Normal view of common carotid artery | 54 |
| Figure (6): | Showing present pleques at common artery bulb | |
| Figure (7): | Showing intime media thickness of 1.2 commoncarotid artery | |
| Figure (8): | Showing the female to male ratio | 57 |
| Figure (9): | Etiology of CKD of participants in our s shown hypertension followed by diabetes are the commonest cause for CKD participants | mellitus among |
| Figure (10): | Showing percentage of serum levels of Fi Growth Factor -23 (FGF-23) among part in our study so 36.7% of them had a (Flevel between 300-400 (pg/dl) | icipants FGF-23) |
| Figure (11): | Showing that more than half of participants had plaques in their common artery | carotid |
| Figure (12): | Showing that >65%OF patients had serun 23 levelOF300-400 Pg/l. | |
| Figure (13): | Showing that as the level of FG increases themore present plaques | ` / |
| Figure (14): | Scatter gram of the correlation levels and common carotid intimathickness (positive correlation) | serum media |

List of Figures (Cont...)

| Fig. No. | Title | Page No. |
|---------------------|--|---------------------------------|
| Figure (15): | Scatter gram of the correlat Fibroblast Growth Factor-23 (FO Hypertension duration (positive corr | GF -23) and |
| Figure (16): | Scatter gram of the correlate Fibroblast Growth Factor-23 (FGI levels and Diabetes Mellitus durate correlation) | F -23) serum ions (negative |
| Figure (17): | Scatter gram of the correlate Fibroblast Growth Factor-23 (FGI levels and serum calcium level correlation) | F -23) serum els (negative |
| Figure (18): | Scatter gram of the correlate Fibroblast Growth Factor-23 (FGI levels and serum phosphorous levels correlation) | F -23) serum vels (negative |
| Figure (19): | Scatter gram of the correlate Fibroblast Growth Factor-23 (FGI levels and serum urea before dial correlation) | F -23) serum ysis (positive |
| Figure (20): | Scatter gram of correlation betwee Growth Factor-23 (FGF -23) seru serum urea after dialysis (positive co | m levels and |
| Figure (21): | Scatter gram of the correlate Fibroblast Growth Factor-23 (FG) levels and estimated glomerular (negative correlation) | F -23) serum filtration rate |
| Figure (22): | Showing that as hypertension increased the more present pla participants (positive correlation) | aques among |

List of Figures (Cont...)

| Fig. No. | Title | Page No. |
|---------------------|--|---------------------------|
| Figure (23): | Showing that the number of patients plaques is more than in absent pladirectly proportional to serum urea and after dialysis | aques and is level before |
| Figure (24): | Showing positive correlation between plaques and common carotid in thickness. | tima media |

List of Abbreviations

| Abb. | Full term |
|--------------|---|
| <i>ABI</i> | Ankle - brachial index |
| AC | Arterial compliance |
| ACEIs | Angiotensin Converting Enzyme Inhibitors |
| <i>AD</i> | Aortic distensibility |
| <i>ADHR</i> | Autosomal dominant hypophosphatemic rickets |
| | Augmentation index |
| <i>ARBs</i> | Angiotensin 2 Receptor Antagonists |
| <i>ARHR</i> | Autosomal recessive hypophosphatemic rickets |
| <i>CAD</i> | Coronary artery disease |
| CaSRs | Calcium-sensing receptors |
| <i>CCIMT</i> | Common carotid intima media thickness |
| Chr 12p13 | Chromosome 12p13 |
| <i>CKD</i> | Chronic Kidney Disease |
| CKD-MBD | Chronic Kidney disease – mineral bone |
| | disorder |
| CTA | Computed tomographic angiography |
| CVD | Cardiovascular Disease |
| CYP24A1 | Cytochrome p450 subfamily A member (Protein coding) |
| CYP27B1 | Cytochrome p450 subfamily B member (Protein coding) |
| DMP-1 | Dentin matrixprotein-1 |
| eGFR | Estimated glomerular filtration rate |
| ELISA | Enzyme-Linked Immunosorbent Assay |
| <i>ESRD</i> | End-stage Renal Disease |
| <i>FD</i> | Fibrous dysplasia |
| <i>FGF</i> | Fibroblast growthfactor |
| | Fibroblast growth factor 23 |
| FGF23-R | Fibroblast growth factor 23-receptor |
| <i>GFR</i> | Glomerular Filtration Rate |

List of Abbreviations (Cont...)

| Abb. | Full term |
|-------------|--|
| HRP | Horseradish Peroxidase |
| <i>IMT</i> | Intima media thickness |
| <i>iPTH</i> | Intact Parathyroid Hormone Serum Levels |
| <i>KD</i> | |
| LL37 | The only human member of cathelicidin family of antimicrobial peptides |
| <i>LRNc</i> | Lipid rich necrotic core |
| <i>MEPE</i> | Matrix Extracellular Phosphoglycoprotein |
| <i>MRI</i> | Magnetic resonance imaging |
| mRNA | Messenger Ribonucleic Acid |
| <i>PCR</i> | Polymerase chain reaction |
| <i>PET</i> | Positron emission tomography |
| <i>PP</i> | Pulse pressure |
| <i>PWV</i> | pulse wave velocity |
| S.Ca | Corrected Serum Calcium |
| S.Creat | Serum Creatinine |
| S.Po4 | Serum Phosphorous |
| <i>SAC</i> | Systemic arterial compliance |
| <i>TCD</i> | Trans cranial Doppler |
| <i>TIO</i> | Tumor induced osteomalacia |
| <i>URR</i> | Urea Reduction Rate |
| <i>VC</i> | Vascular calcification |
| <i>VDRs</i> | Vitamin D receptors |
| <i>XLH</i> | X -linked hypophosphatemia |

ABSTRACT

Background: FGF23 is a free circulating hormone secreted by osteocytes affecting mainly phosphate metabolism as it inhibits its renal tubular reabsorption by suppressing the expression of luminal sodium-phosphate co –transporters (Na Pi).

Aim of the Work: Aim of study is to verify the usefulness of FGF23 as a marker for diagnosis of arterial stiffness in CKD patients on regular hemodialysis (3 sessions per week, 4 hours each).

Patients and Methods: The present study enrolled 30 living end stage renal disease patients on regular hemodialysis randomly slected from hemodialysis unit at Ain Shams university hospitals after exclusion of patients of known cardiovascular disease or ischemic heart disease, also patients of age below 18 years and above 50 years were excluded as well as patients having arterio venous fistulas on both arms. All patients were subjected to complete medical history taking, including (Age, Sex, Etiology of chronic kidney disease, drugs and duration of dialysis), and detailed clinical examination was done.

Results: In this study patients have elevated serum levels of FGF-23 ranging from 100 up to 700 pg/ml. when the normal refrence range is 18-108 pg/ml. Also our study result revealed a statistical significance of negative correlation between FGF-23 and diabetes mellitus duration, serum phosphorous, corrected calcium and estimated glomerular filtration rate as well. The current study shows statistical correlation of positive significance between FGF-23 and hypertension duration where, common carotid artery intima media thickness as well as present plaques in common carotid artery. Moreover there is no statistical significant correlation between FGF-23 and pulse pressure.

Conclusion: FGF23 serum levels are markedly elevated in chronic kidney disease CKD and among patients on regular hemodialysis causing arterial stiffness.

Keywords: Fibroblast Gross Factor-23; Carotid Artery Stiffness; Hemodialysis

Introduction

pibroblast growth factor 23 (FGF-23) is a circulating osteocyte derived hormone that is often seen in elevated serum concentrations in patients with advanced chronic kidney disease (CKD) (*Gutierrez et al.*, 2005).

Fibroblast growth factor 23 (FGF-23) plays a key role in regulating serum phosphorous concentration by promoting phosphorous excretion and inhibiting 1 alpha hydroxylase in the renal proximal tubule (*Burnett et al.*, 2006).

FGF-23 requires its co-receptor which is a Klotho-receptor to bind to target tissue and exert its biological effects and most studies have showed that there is no expression of Klotho-receptor in human vascular cells as the one done by (Scialla et al., 2013 and Lindberg et al., 2013).

However, there is a study suggested that, the expression of Fibroblast growth factor-23 (FGF-23) may be induced by vitamin D.receptor activator in human aortic smooth muscle cells as demonstrated by (*Lim et al.*, 2012).

Elevated serum Fibroblast growth factor-23 (FGF-23) is associated with cardiovascular disease (CVD), yet the mechanism remain uncertain Since, FGF-23 is integral in regulating phosphorous and vitamin D. metabolism, not only it responds to increased serum phosphorous, but it may also induce arterial calcification and stiffness as demonstrated by

several studies like the one done by (Jeffry et al., 2014) and also there are many previous studies like those done by (Nasrallah et al., 2010 and Desfardins et al., 2012) that, have observed associations of elevated serum Fibroblast growth factor 23 (FGF-23) with arterial calcification and stiffness.

However the study done by (Scialla et al., 2013) revealed that Fibroblast growth factor-23 FGF23 is not associated with and does not induce arterial calcification.

Multiple community- based studies have demonstrated associations between measures of increased arterial stiffness (Peralta et al., 2012) and high ankle - brachial index (ABI) (OH et al., 2006) with increased cardiovascular morbidity and mortality, as well as incident hypertension, coronary heart disease, stroke, heart failure and kidney function decline

AIM OF THE WORK

im of study is to verify the usefulness of FGF23 as a marker for diagnosis of arterial stiffness in CKD patients on regular hemodialysis (3 sessions per week, 4 hours each).